On July 25, 2023 Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine, reported a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products (Press release, Illumina, JUL 25, 2023, View Source [SID1234633421]). The agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques, improving patient access to personalized cancer treatment options.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are proud to partner with Pillar to provide products that will improve care for patients with advanced and high-risk cancer," said Phil Febbo, chief medical officer of Illumina. "By leveraging Pillar’s targeted sequencing technology alongside Illumina’s state-of-the-art sequencing and bioinformatics solutions, we will enable rapid and focused genomic profiling of tumors, which is essential to facilitate personalized therapy in healthcare systems across the globe."
Pillar’s targeted assays help oncologists and researchers identify mutations that drive tumor growth. This knowledge is pivotal in making informed decisions about cancer treatment. By gaining an understanding of the genomic landscape of the tumor, clinicians can tailor treatment options such as targeted therapies and immunotherapies to suit each patient’s needs. This personalized approach has the potential to result in more effective and precise interventions.
"Pillar Biosciences is committed to enabling global access to our high-value genomic profiling assays to empower better-informed precision patient treatment," said Randy Pritchard, CEO of Pillar Biosciences. "This agreement will facilitate seamless integration between Pillar Biosciences assays and Illumina sequencers, delivering a streamlined workflow and complementary product offerings and leading to faster turnaround times for patients."
Pillar’s suite of oncology assays can be used on any of Illumina’s sequencers. Assay offering will depend on the region. Commercial availability of Pillar’s assays through Illumina is set to begin this month.